Lexicon Pharmaceuticals (LXRX) Stock Forecast & Price Target

Compare

1,743 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

LXRX Analyst Ratings

Strong Buy

3 Buy

0 Hold

0 Sell

Based on 3 analysts giving stock ratings to

Lexicon

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

LXRX Stock 12 Month Forecast

Average Price Target

$3.97

▲(222.76% Upside)

Based on 3 Wall Street analysts offering 12 month price targets for Lexicon Pharmaceuticals in the last 3 months. The average price target is $3.97 with a high forecast of $6.00 and a low forecast of $1.90. The average price target represents a 222.76% change from the last price of $1.23.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","3":"$3","5":"$5","7":"$7","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.97,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.97</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.90</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1,3,5,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.36,1.716923076923077,2.073846153846154,2.430769230769231,2.787692307692308,3.144615384615385,3.5015384615384617,3.8584615384615386,4.2153846153846155,4.572307692307692,4.929230769230769,5.286153846153846,5.643076923076923,{"y":6,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.36,1.560769230769231,1.7615384615384617,1.9623076923076925,2.163076923076923,2.363846153846154,2.5646153846153847,2.7653846153846153,2.9661538461538464,3.1669230769230774,3.367692307692308,3.5684615384615386,3.769230769230769,{"y":3.97,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.36,1.4015384615384616,1.4430769230769231,1.4846153846153847,1.5261538461538462,1.5676923076923077,1.6092307692307692,1.6507692307692308,1.6923076923076923,1.7338461538461538,1.7753846153846153,1.8169230769230769,1.8584615384615384,{"y":1.9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.8,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 14</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.74,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 14</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.76,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.7,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.46,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.72,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.62,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.88,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.07,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.12,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.36,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$6.00

Average Price Target$3.97

Lowest Price Target$1.90

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yigal Nochomovitz

Citi

$1.9

Buy

54.47%

Upside

Reiterated

12/19/25

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN), Lexicon Pharmaceuticals (NASDAQ: LXRX) and Pfizer (NYSE: PFE)We hosted LXRX’s CEO Dr. Mike Exton, CMO Dr. Craig Granowitz, and CFO Scott Coiante today as part of Citi’s SMID Series (replay here). Mgmt. gave a rundown of their three programs (LX9851, pilavapadin, and sotagliflozin), highlighting the following upcoming milestones — 1) partner Novo Nordisk to take LX9851 into first- in-human dosing in 2026; 2) potential approval of Zynquista (sotagliflozin) in T1D in 2026, contingent on NDA resubmission; 3) conclusion of the EOP2 process with the FDA for pilavapadin in DPNP in early 2026, setting up for a possible pain partnership in the weeks-to- months thereafter (we continue to expect a meaningful rerating of the stock if a partner is selected); and 4) complete enrollment in the pivotal SONATA-HCM trial in 1H26, still targeting data readout in 1Q27.

Joseph Pantginis

H.C. Wainwright

Buy

225.20%

Upside

Reiterated

12/10/25

Lexicon Pharmaceuticals: Buy Rating Backed by Promising Cardiovascular and Neuropathic Pain Advances

Yasmeen Rahimi

Piper Sandler

Buy

387.80%

Upside

Reiterated

11/10/25

Analysts Offer Insights on Healthcare Companies: Moderna (NASDAQ: MRNA), McKesson (NYSE: MCK) and Lexicon Pharmaceuticals (NASDAQ: LXRX)

Roanna Ruiz

Leerink Partners

Hold

-18.70%

Downside

Reiterated

08/07/25

Balanced Outlook for Lexicon Pharmaceuticals Amid Strategic Gains and Revenue Challenges

Andrew Tsai

Jefferies

$0.7→$0.85

Hold

-30.89%

Downside

Reiterated

08/06/25

Jefferies Reaffirms Their Hold Rating on Lexicon Pharmaceuticals (LXRX)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yigal Nochomovitz

Citi

$1.9

Buy

54.47%

Upside

Reiterated

12/19/25

Joseph Pantginis

H.C. Wainwright

Buy

225.20%

Upside

Reiterated

12/10/25

Lexicon Pharmaceuticals: Buy Rating Backed by Promising Cardiovascular and Neuropathic Pain Advances

Yasmeen Rahimi

Piper Sandler

Buy

387.80%

Upside

Reiterated

11/10/25

Analysts Offer Insights on Healthcare Companies: Moderna (NASDAQ: MRNA), McKesson (NYSE: MCK) and Lexicon Pharmaceuticals (NASDAQ: LXRX)

Roanna Ruiz

Leerink Partners

Hold

-18.70%

Downside

Reiterated

08/07/25

Balanced Outlook for Lexicon Pharmaceuticals Amid Strategic Gains and Revenue Challenges

Andrew Tsai

Jefferies

$0.7→$0.85

Hold

-30.89%

Downside

Reiterated

08/06/25

Jefferies Reaffirms Their Hold Rating on Lexicon Pharmaceuticals (LXRX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Lexicon Pharmaceuticals

1 Month

xxx

Success Rate

7/17 ratings generated profit

Average Return

-2.87%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 41.18% of your transactions generating a profit, with an average return of -2.87% per trade.

3 Months

xxx

Success Rate

5/17 ratings generated profit

Average Return

+0.10%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 29.41% of your transactions generating a profit, with an average return of +0.10% per trade.

1 Year

Joseph PantginisH.C. Wainwright

Success Rate

9/17 ratings generated profit

Average Return

+19.12%

reiterated a buy rating 17 days ago

Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 52.94% of your transactions generating a profit, with an average return of +19.12% per trade.

2 Years

xxx

Success Rate

8/17 ratings generated profit

Average Return

+18.44%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 47.06% of your transactions generating a profit, with an average return of +18.44% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LXRX Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, LXRX has received 7 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. LXRX average Analyst price target in the past 3 months is 3.97.

Each month's total comprises the sum of three months' worth of ratings.

LXRX Financial Forecast

LXRX Earnings Forecast

Next quarter’s earnings estimate for LXRX is -$0.07 with a range of -$0.08 to -$0.06. The previous quarter’s EPS was -$0.04. LXRX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year LXRX has Performed in-line its overall industry.

LXRX Sales Forecast

Next quarter’s sales forecast for LXRX is $3.14M with a range of $0.00 to $6.80M. The previous quarter’s sales results were $14.18M. LXRX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year LXRX has Performed in-line its overall industry.

LXRX Stock Forecast FAQ

What is LXRX’s average 12-month price target, according to analysts?

Based on analyst ratings, Lexicon Pharmaceuticals’s 12-month average price target is 3.97.

What is LXRX’s upside potential, based on the analysts’ average price target?

Lexicon Pharmaceuticals has 222.76% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is LXRX a Buy, Sell or Hold?

Lexicon Pharmaceuticals has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.

What is Lexicon Pharmaceuticals’s price target?

The average price target for Lexicon Pharmaceuticals is 3.97. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $6.00 ,the lowest forecast is $1.90. The average price target represents 222.76% Increase from the current price of $1.23.

What do analysts say about Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of LXRX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Lexicon Pharmaceuticals (LXRX) Stock Forecast & Price Target

LXRX Analyst Ratings

LXRX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Lexicon Pharmaceuticals

LXRX Analyst Recommendation Trends

LXRX Financial Forecast

LXRX Earnings Forecast

LXRX Sales Forecast

LXRX Stock Forecast FAQ

Detailed List of Analyst Forecasts